A cost utility analysis for the management of acute exacerbations of chronic rhinosinusitis
Open Access
- 20 September 2024
- journal article
- research article
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (2) , 109-119
Abstract
Background: The management of acute exacerbations of chronic rhinosinusitis (AECRS) is understudied and the most cost‐effective management of AECRS has not been previously investigated. The aim of this study is to determine the most cost‐effective strategy for the initial management of AECRS.Methods: The study design consisted of a decision‐tree economic model comparing three different initial strategies for managing a patient perceived AECRS: observation, upfront rescue medications, or clinic visit with diagnostic nasal endoscopy (DNE). The primary study outcome was the disease burden of a single AECRS, which was determined by the health utility value and the duration of symptoms. Strategies with an incremental cost‐effectiveness ratio < $50,000/quality‐adjusted life year (QALY) or equivalently < $137/quality‐adjusted life day (QALD) were considered cost‐effective.Results: Observation was the most cost‐effective strategy at a willingness to pay of $137 per QALD. One‐way sensitivity analysis demonstrated that observation was more effective than upfront rescue medications when the probability of bacterial infection as the cause of AECRS was <24.0%. Upfront rescue medications wer more cost effective than observation when the probability of bacterial infection exceeded 49.0%. Clinic visit with DNE was the most effective strategy to manage an AECRS, but it was not considered cost‐effective.Conclusion: Observation is the most cost‐effective strategy for the initial management of AECRS when there is a low likelihood of bacterial infection. When the probability of bacterial etiology of AECRS exceeds 49.0%, upfront rescue medications proved to be the most cost‐effective strategy.Keywords
This publication has 41 references indexed in Scilit:
- Establishment of a duration criterion for acute exacerbations of chronic rhinosinusitis through qualitative analysis of patient experiencesInternational Forum of Allergy & Rhinology, 2023
- Oral Corticosteroids Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis Without Nasal PolyposisJAMA Otolaryngology–Head & Neck Surgery, 2021
- International consensus statement on allergy and rhinology: rhinosinusitis 2021International Forum of Allergy & Rhinology, 2020
- Antibiotics for acute rhinosinusitis in adultsCochrane Database of Systematic Reviews, 2018
- Association between systemic antibiotic and corticosteroid use for chronic rhinosinusitis and quality of lifeThe Laryngoscope, 2017
- What drives productivity loss in chronic rhinosinusitis? A SNOT‐22 subdomain analysisThe Laryngoscope, 2017
- Amoxicillin‐clavulanate for patients with acute exacerbation of chronic rhinosinusitis: a prospective, double‐blinded, placebo‐controlled trialInternational Forum of Allergy & Rhinology, 2016
- Measurement and comparison of health utility assessments in chronic rhinosinusitisInternational Forum of Allergy & Rhinology, 2015
- The prevalence of bacterial infection in acute rhinosinusitis: A Systematic review and meta‐analysisThe Laryngoscope, 2014
- Productivity costs in patients with refractory chronic rhinosinusitisThe Laryngoscope, 2014